Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258800 | 0.90 | MEN1 (0.47) | MEN1TP53PABPC1KMT2ATDP1 | |
| SCHEMBL4862100 | 0.82 | MEN1 (0.49) | MEN1TP53PABPC1KMT2ATDP1 | |
| SCHEMBL4019976 | 0.82 | MEN1 (0.49) | MEN1TP53PABPC1KMT2ATDP1 | |
| SCHEMBL5016756 | 0.82 | MEN1 (0.52) | MEN1TP53PABPC1KMT2ATDP1 | |
| SCHEMBL4022616 | 0.82 | MEN1 (0.52) | MEN1TP53PABPC1KMT2ATDP1 | |
| SCHEMBL10684276 | 0.82 | MEN1 (0.49) | MEN1TP53PABPC1KMT2ATDP1 | |
| SCHEMBL5015508 | 0.81 | MEN1 (0.51) | MEN1TP53PABPC1KMT2ATDP1 | |
| SCHEMBL4258804 | 0.79 | MEN1 (0.47) | MEN1TP53PABPC1KMT2ATDP1 | |
| SCHEMBL454840 | 0.79 | MEN1 (0.47) | MEN1TP53PABPC1KMT2ATDP1 | |
| SCHEMBL5717573 | 0.78 | MEN1 (0.49) | MEN1TP53PABPC1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524823-B2 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2009-04-28 | — | — | US | disclosed |
| EP-1846430-B1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| EP-1846430-A1 | NEW MACROLIDES | Basilea Pharmaceutica AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-20060264387-A1 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2006-11-23 | — | — | US | disclosed |
| WO-2006084410-A1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264387-A1 | Macrolides | PPME1, MGAM, SMPD1 | MEN1 1597/4885TP53 4833/4885PABPC1 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.